Coinciding with the celebration on May 20 of the Clinical Trials World Day, this Monday the fifth chapter of the Cancer 360º podcast entitled “Clinical trials; one more alternative in the treatment of cancer.”
In this chapter, journalist Adam Martín talks with Elena Garralda, Enriqueta Felip, Joan Carles, Francesc Bosch, Laura Bascuñana and Ignacio Carcela about how the conception of the clinical trial has changed, how in recent years has become another therapeutic alternative for cancer patients. We will also know how clinical trials are designed, which are their phases and what professionals are involved.
This podcast also reflects on the importance of trials in the early phases and, specifically, explains how the Cancer Molecular Therapy Research Unit (UITM) – CaixaResearch works.
VHIO, a reference in the development of increasingly innovative and personalized clinical trials
The VHIO Clinical Trials Office continually works to improve workflows with all cross-functional teams involved in clinical trials to optimally manage complex and increasingly demanding protocols. At the end of last year, the VHIO had 869 active clinical trials underway, most of them in the fields of medical oncology (677), but also hematology (184) and radiotherapy. VHIO clinical research also covers all phases of clinical trials that represent treatment opportunities for cancer patients with 253 in phase I, 240 in phase II, 294 in phase III and 82 in phase IV and others. Furthermore, 1,685 patients participated in these studies throughout the year.
The number of trials in early phases of the UITM-CaixaResearch Cancer Molecular Therapy Research Unit stands out, a very consolidated unit that promotes a close connection between oncological care and research, establishing new therapeutic strategies for patients, working in collaboration with several European projects in the frame of the Horizon 2020 Program of the European Cancer Mission such as PrimeROSE, PCM4EU, CCE_DART, PragmaTIL and canSERV. Likewise, since 2014 it has participated with Cancer Core Europe, a consortium whose objective is to accelerate oncological research in Europe through different studies and initiatives coordinated between 7 European research centers, for the benefit of patients.
